Bifidobacterium lactis V9

Bifidobacterium lactis V9 is a probiotic strain of the species Bifidobacterium animalis subsp. lactis, originally isolated from the intestinal tract of healthy Mongolian children in Inner Mongolia in 2005 and identified by 16S rDNA sequencing[2]. It is notable for its strong tolerance to artificial gastric and intestinal fluids, high survival rate under acidic and bile salt conditions, and stable colonization ability in the human gut[2]. As a live biotherapeutic product, it has demonstrated positive therapeutic potential in several gastrointestinal disorders including irritable bowel syndrome (IBS), diarrhea, ulcerative colitis (UC), and dextran sulfate sodium (DSS)-induced colitis models[2]. In clinical studies involving patients with polycystic ovary syndrome (PCOS), oral administration of B. lactis V9 was associated with significant improvements in metabolic parameters such as reduced luteinizing hormone (LH) levels and increased short-chain fatty acids (SCFAs)[1][3][5]. The proposed mechanism involves modulation of the intestinal microbiome composition—promoting beneficial bacteria while inhibiting harmful ones—and influencing gut-brain mediators that regulate sex hormones via the gut-brain axis[1][3][5].

Other names

B. lactis V9Bifidobacterium animalis subsp. lactis V9